PA) - Erle S. Robertson, PhD, an Associate Professor
of Microbiology at the University of Pennsylvania School
of Medicine, has edited a compendium, the largest to date,
on the Epstein-Barr virus (EBV). The 33-chapter, 770-page review
is entitled simply Epstein-Barr Virus. The book is published
by Caister/Horizon Academic Press. This is the first volume of its
kind dealing solely with Epstein-Barr virus and is expected to be
the reference guide for all major works on the virus.
Topics covered include: Discovery, history and seroepidemiology;
EBV and the immune response; EBV genetics; EBV infection and persistence;
latency; lytic proteins and reactivation control; vaccine approaches;
animal models; and the future of EBV studies. The first chapter,
"The Origins of EBV Research," is written by Sir Anthony
Epstein from the University of Oxford, John Radcliffe Hospital,
Oxford, United Kingdom, who named the virus along with his coworker
Bert Achong and graduate student Yvonne Barr while studying at the
Middlesex Hospital in London, UK in 1962.
Epstein Barr virus (EBV) is a human gamma herpes virus that remains
one of the most successful viral parasites known to medical researchers.
EBV is the agent of infectious mononucleosis and is the major biological
cofactor contributing to a number of human cancers including B-cell
neoplasms (Burkitt's lymphoma, Hodgkin's disease and immunoblastic
lymphomas), certain forms of T-cell lymphoma, and some epithelial
tumors (nasopharyngeal carcinomas and gastric carcinomas).
“This exceptional volume represents the first extensive reference
guide for the field of EBV research, which is intended to impart
to readers a sense of discovery, a discussion of initial and current
hypotheses, as well as strategies for vaccine development,”
says Robertson, who also wrote a chapter on EBV and the cell cycle,
with Jason S. Knight, a graduate student in the
Robertson lab. “It provides a wealth of information spanning
40 years of research, but at the same time clearly demonstrates
the need for continuing studies.” Robertson is also the Director
of the Tumor Virology Program at Penn's Abramson Cancer
PENN Medicine is a $2.7 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn’s School of Medicine is ranked #2 in the nation
for receipt of NIH research funds; and ranked #4 in the nation in
U.S. News & World Report’s most recent ranking of top
research-oriented medical schools. Supporting 1,400 fulltime faculty
and 700 students, the School of Medicine is recognized worldwide
for its superior education and training of the next generation of
physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System comprises: its
flagship hospital, the Hospital of the University of Pennsylvania,
consistently rated one of the nation’s “Honor Roll”
hospitals by U.S. News & World Report; Pennsylvania Hospital,
the nation's first hospital; Penn Presbyterian Medical Center; a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home health care and hospice.